Nebenwirkungen · Ebixa
Ebixa 10 mg film-coated tablets Ebixa 20 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 5
HOS-111453 · Präparat HOS-093529
Summary of the safety profile In clinical trials in mild to severe dementia, involving 1,784 patients treated with Ebixa and 1,595 patients treated with placebo, the overall incidence rate of adverse reactions with Ebixa did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity. The most frequently occurring adverse reactions with a higher incidence in the Ebixa group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-08T01:00:00Z · SHA-256 fb703506cb848cecf2e6b0e6b12a70b0eed07252984425ca4decbb1c1cda36ff · Passage 3cf5ba3ae0d28a19c73c333881d727be1b267a76d8b43af8cdd688ef827a9651 · Zeichen 0–600 im Abschnitt